NSFC spurs significant basic research progress of respiratory medicine in China

Ruijuan Sun1*, Feng Xu1,2*, Chen Wang3 and Erdan Dong1

1 Department of Health Sciences, National Natural Science Foundation of China, Beijing, China
2 Department of Infectious Diseases, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 Department of Respiratory and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China

Abstract
Over the years, research in respiratory medicine has progressed rapidly in China. This commentary narrates the role of the National Natural Science Foundation of China (NSFC) in supporting the basic research of respiratory medicine, summarizes the major progress of respiratory medicine in China, and addresses the main future research directions sponsored by the NSFC.

Key words
China – National Natural Science Foundation of China – respiratory medicine

Correspondence
Prof. Erdan Dong, MD, PhD, Department of Health Sciences, National Natural Science Foundation of China, China. Tel: 86-10-62326982 Fax: 86-10-62328940 email: donged@nsfc.gov.cn
Prof. Ruijuan Sun, PhD, Department of Health Sciences, National Natural Science Foundation of China, China. Tel: 010-62328621 Fax: 010-62328940 email: sunrj@nsfc.gov.cn

Received: 25 March 2015
Revision requested: 10 July 2015
Accepted: 13 July 2015
DOI:10.1111/crj.12351

Authorship and contributorship
Ruijuan Sun and Feng Xu designed and drafted the manuscript; Feng Xu collected and analyzed data; Erdan Dong and Chen Wang revised the manuscript and outlined its structure. The manuscript has been read and approved by all coauthors.

Ethics
This study is in accordance with the Author Guidelines.

Conflicts of interest
The authors have stated explicitly that there are no conflicts of interest in connection with this article.

*Dr. Ruijuan Sun and Dr. Feng Xu equally contribute to this work and share the co-first authorship.
Introduction

Respiratory diseases seriously affect the health of the Chinese population. With the economic development and environmental deterioration because of industrialization in China, respiratory diseases cause 10.56% and 13.31% of mortality in rural and urban China, respectively, (ranking number 3 and 4 among the leading causes of death) (1).

As the largest grant funding agency for basic research in China, National Natural Science Foundation of China (NSFC), which was established in 1986, dramatically spurs vigorous advances in respiratory medicine to understand and treat diseases. The Department of Health Sciences (DHS) at the NSFC gives priority to basic research about the causes, diagnosis, prevention and cure of human diseases and the application of that knowledge to enhance human health of the nation. The objective of DHS is to facilitate the development of health sciences in China. Within DHS, the Division of Respiratory Diseases (DRD) is responsible for supporting basic research in diverse respiratory diseases with the exception of respiratory malignancies. Areas of research supported include bronchial asthma, Chronic Obstructive Pulmonary Disease (COPD), interstitial lung diseases, acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), pulmonary hypertension (PH), pulmonary embolism, respiratory failure, sleep disordered breathing, lung transplantation and protection.

NSFC promotes persistent basic research progress of respiratory medicine in China

Over the years, NSFC has given comprehensive, long-term, multi-levels and large-scale funding to relevant researches in respiratory diseases. The number of funded projects and the amount of grants in respiratory medicine are shown in Figs. 1 and 2, respectively. Funding has rapidly increased since 2001, especially after 2009. The detailed supporting information from 18 different DRD-funded research areas (coded as H0101–H0118) is listed in Figs. 3 and 4. Under the sponsorship of the NSFC in the past 26 years, a dozen of active research groups have obtained significant achievements in the diverse areas of respiratory medicine. Major and important work by researchers of China is reviewed below.

Respiratory infections

China has made great contributions to the control of pulmonary infections, in particular concerning a couple of new pulmonary viral diseases, causative of a pandemic, great financial loss and social panic. In the year 2003, Nanshan Zhong (Guangzhou Medical College) and other researchers isolated severe acute respiratory syndrome (SARS) coronavirus (CoV) in Guangdong. They demonstrated SARS CoV was responsible for the epidemic outbreak and the prototypical SARS-CoV strain found in other countries (2). Zhong also proposed corticosteroid treatment for critical SARS and confirmed proper corticosteroid use decreased mortality and hospital stay, and was not significantly associated with secondary lower respiratory infection or other severe complications (3, 4). Further studies revealed detectable persistence of IgG antibodies and neutralizing viral antibodies for up to 720 days. (5). In a rhesus macaque model, potent siRNA inhibitors of SARS-CoV provided relief from fever, diminished viral levels and reduced acute diffuse alveoli damage (6). The group of Chengyu Jiang (Chinese Academy of Medical Sciences, CAMS) reported the entry of SARS-CoV into cells was mediated by a heparin sulfate proteoglycans-mediated, but clathrin- and caveola-independent mechanism (7, 8). Zhengli Shi...
and coworkers reported whole-genome sequences of two novel bat CoVs from Chinese horseshoe bats in Yunnan, China: RsSHC014 and Rs3367. These viruses were far more closely related to SARS-CoV than any previously identified bat CoVs, particularly in the receptor binding domain (RBD) of the spike protein. Most importantly, they found the first recorded isolation of a live SARS-like-CoV strain, with typical CoV morphology sharing 99.9% sequence identity to Rs3367, utilizing angiotensin-converting enzyme 2 from humans, civets and Chinese horseshoe bats for cellular entry. These results provide the strongest evidence that Chinese horseshoe bats are natural reservoirs of SARS-CoV (9).

The newly emergent Middle East respiratory syndrome CoV (MERS-CoV) causes severe pulmonary disease in humans, representing the second example of a highly pathogenic CoV. Fu Gao (Chinese Center for Disease Control and Prevention, CCDC) delineated the specific interaction between the free RBD of the MERS-CoV spike protein and CD26, the cellular receptor for MERS-CoV (10). Chuan Qin (CAMS) developed rhesus macaques as a model for MERS-CoV. The infected monkeys exhibited clinical signs of disease, viral replication, histological lesions and produced neutralizing antibody (11). Taijiao Jiang (CAS) developed a new computational method PREDAC, predicting antigenic clusters of H3N2 influenza virus with high accuracy from viral hemagglutinin (HA) sequences. The coupling of large-scale HA sequencing with PREDAC can significantly improve vaccine strain recommendation (12). Jiang’s work provides an urgently needed tool for rapid and large-scale analysis of HA receptor specificities for global influenza surveillance. The group of Chengyu Jiang found autophagic cell death of alveolar epithelial cells plays a crucial role in the high mortality rate of H5N1 infection, and autophagy-blocking agents might be useful against H5N1-induced lung injury.
(13). IL-17 Monoclonal antibodies were reported to be potential treatment agent for H1N1 virus (14). Hongyan Wang (CAS) and coworkers first demonstrated that adhesion and degranulation-promoting adapter protein (ADAP) regulates the positive feedback loop of TGF-β1 production and TGF-β1-induced CD103 expression in CD8+ T cells via the TβRI-TRAF6-TAK1-SMAD3 pathway and protects from influenza virus (i.e. H5N1 or H1N1) infection (15). Chen Wang (Capital Medical University) and coworkers reported oseltamivir and maxingshan- yinqiaosan, alone and in combination, reduced time to fever resolution in H1N1 patients (16). During an influenza pandemic in mainland of China in 2013, Yuelong Shu (CCDC) and coworkers reported isolation of a novel re-arrangement of avian-origin influenza A virus, identified as H7N9. Further sequencing analyses revealed, all gene segments from the virus were of avian origin (17). Lanjuan Li (Zhejiang University)’s team found a similar viral isolate from patients and epidemiologically linked market chickens. The H7 of the isolated viruses was closest to that of the H7N3 virus from domestic ducks in Zhejiang, whereas the N9 was closest to that of the wild bird H7N9 virus in South Korea. Gln226Leu and Gly186Val substitutions in human virus H7 and the PB2 Asp701Asn mutation were identified (18). Huan Chen (Gansu Agricultural University) and coworkers systematically analyzed H7N9 viruses isolated from birds and humans. They determined viruses isolated from birds were nonpathogenic in ducks, ducks and mice, but viruses isolated from humans caused up to 30% body weight loss in mice. One virus isolated from humans was highly transmissible in ferrets by respiratory droplet (19). Chuan Qin also reported that H7N9 virus was capable of transmission between ferrets via low level respiratory droplets. Four mutations were further identified in the virus isolated from the contact ferret (20). Fu Gao had evaluated the viral HA receptor-binding properties of two human H7N9 isolates and found that SH-H7N9 HA preferentially binds the avian receptor analog, whereas AH-H7N9 HA binds both avian and human receptor analogs. Furthermore, an AH-H7N9 mutant HA (Leu226→Gln) exhibited dual receptor-binding properties, which indicated AH-H7N9 can bind human receptors while retaining avian receptor-binding properties (21). The prognosis of H7N9 infection is poor. Lanjuan Li and coworkers performed a comprehensive study to identify prognostic factors for H7N9, and found chronic heart disease was associated with increased hospitalization risk (22). The increased plasma levels of angiotensin II in H7N9 patients are associated with disease severity and mortality. Moreover, the predictive value of angiotensin II is greater than that of C-reactive protein, and some clinical parameters such asPaO2/FiO2 ratio (23). A national monitoring network in China for emergent infections, established after the SARS crisis in 2003, was crucial to timely prevention and treatment of the H7N9 infection.

The infection of bacteria is much more common among pulmonary infectious diseases. *Staphylococcus aureus* is one of the leading causes of severe pneumonia and sepsis. Macrophage polarization is critical for dictating host defense against pathogens and injurious agents. Feng Xu (Zhejiang University) found M1 macrophage skewing was regulated by PI3-K/Akt1-mediated miR-155/SOCS1 axis. Blocking of miR-155 in macrophages from Akt1−/− mice or knockdown of SOCS1 in cells from wild-type mice disabled or enabled, respectively, an M1 macrophage shift and antibacterial response (24). Guangwei Liu (Fudan University) indicated that the Akt1-STAT1 signaling axis negatively regulates neutrophil recruitment and activation in *S. aureus* infection in mice (25). These results implicate Akt1 as a promising target for the therapeutic intervention in *S. aureus* infection. Using a mouse model of secondary *Pseudomonas aeruginosa* pneumonia during sepsis-associated immunosuppression, Ju Cao (Chongqing Medical University) demonstrated IL-4 deficiency mice exhibited enhanced lung inflammation, neutrophil recruitment to airspaces and elevated pulmonary cytokine production, leading to impaired host defense (26). Similarly, IL-27 is also an important mediator of sepsis-induced impairment of pulmonary immune response upon *Pseudomonas aeruginosa* infection (27). Jieming Qu (Shanghai Jiao Tong University) found adipose tissue-derived mesenchymal stem cells (ASCs) exhibited protective effects on *P. aeruginosa* pulmonary infection by inhibiting production of prostaglandin E2, and improving phagocytosis and the bactericidal properties of macrophages. ASCs may provide a new strategy for pulmonary bacterial infections (28).

Fungal infection becomes more common, particularly among the elderly and immunocompromised people in China. Understanding of host-defense fundamental mechanisms may lead to the development of effective preventive and therapeutic strategies. Hui Xiao (CAS) found SHP-2 gene ablation in dendritic cells (DCs) and macrophages impaired the tyrosine kinase Syk-mediated signaling and abrogated pro-inflammatory response following fungal stimulation. SHP-2 facilitated the recruitment of Syk to the C-type lectin receptor (CLR) dectin-1 or the adaptor FcRγ, through its N-SH2 domain and a carboxy-terminal immunoreceptor tyrosine-based activation motif. DC-derived SHP-2 was crucial for anti-fungal responses of the TH17 cells in controlling infection with Candida.
albicans. This study highlights the importance of the concerted actions of different CLRs on various cells of the innate immune system against fungi (29). Vitamin D plays an important role in pulmonary immunity, and its deficiency has been linked to various respiratory infections. Yi Shi (Nanjing University) identified that $\beta$-glucan, the major *Aspergillus fumigatus* cell wall component, as the major agent for upregulation of 12-hydroxylase and vitamin D receptor, and vitamin D production in human bronchial epithelial cells. Upon *A. fumigatus* exposure, vitamin D deficiency led to higher mortality and greater fungal load, which was accompanied with enhanced and sustained expression of inflammatory cytokines (30). Jieming Qu demonstrated transient overexpression of IFN-$\gamma$ could augment host defense against *Aspergillus* by upregulation of killing ability of alveolar macrophages and lung leukocytes (31).

Tuberculosis (TB) is a major health problem in China. According to the 2014 WHO report on tuberculosis, there were an estimated 980 thousands incident cases of TB in mainland of China. The host immune system plays an important role in the development and control of disease during tuberculosis infection. Haiying Liu (Peking Union Medical College) and her coworkers investigated the clinical significance and immunological role of Gab2 in Mycobacterium TB infection. They found Gab2 negatively correlated with the level of TB antigen-specific IFN-$\gamma$ secretion, and down-regulation of Gab2 showed a protective function against TB (32). Cuihua Liu (CAS) found that MTB tyrosine phosphatase PtpA suppressed innate immunity dependent on pathways of the kinases Jnk and p38 and NF-$\kappa$B by exploiting host ubiquitin. The host adaptor TAB3 mediated NF-$\kappa$B signaling by sensing ubiquitin chains, and PtpA blocked this process by competitively binding the ubiquitin-interacting domain of TAB3. Therefore, targeting of ubiquitin-PtpA interaction could be a potential tuberculosis treatment (33). Baoxue Ge (Tongji University) identified Epstein-Barr virus-induced gene 3(EBI3) rs4740 polymorphism is closely associated with susceptibility to pulmonary TB and the elevation and enrichment of EBI3 in the lung may contribute to the exacerbation of mycobacterial infection (34). Mucosal-associated invariant T (MAIT) cells have been shown to play an important role in host defense against mycobacterial infection. Xiaoxing Cheng (309th Hospital) compared the functions of MAIT cells between patients with active TB and healthy control subjects. They found MAIT cells in patients with active TB exhibited elevated expression of programmed death-1 (PD-1), and blockade of PD-1 signaling resulted in a higher frequency of BCG-stimulated IFN-$\gamma$ production in MAIT cells (35). Drug-resistant TB is a serious clinical problem. Shengjie Tang (Capital Medical University) conducted a prospective, multicentre, randomized study to evaluate the efficacy, safety and tolerability of linezolid in patients with extensively drug-resistant TB in China. The treatment success rate in linezolid therapy group was reported to 69.7%, significantly higher than that in the control group (34.4%) (36).

### ALI/ARDS

China makes substantial efforts to investigate the cellular and molecular mechanisms of ALI/ARDS during recent years (37). Chunxue Bai (Fudan University) identified both capillary and alveolar epithelium stress failure contributed to high altitude pulmonary edema, and keratinocyte growth factor-2 (KGF-2) pre-administration significantly reduced lung injury and improved survival (38, 39). Later, the protective efficacy of KGF had been further confirmed in a human lung injury model by others (40). Bai et al. demonstrated Prdx6 deletion exacerbated lung injury induced by LPS (lipopolysaccharide) via reduced capability to clear $\mathrm{H}_2\mathrm{O}_2$ (41). Feng Xu (Zhejiang University) and Liyun Shi (Hangzhou Normal University) recently reported miR-127 modulates macrophage polarization and promotes LPS induced-lung inflammation and injury by activating the Bcl6-Dusp1-JNK pathway. MiR-127 is a potential molecular target for the treatment of ALI (42). Intrapleural administration of mesenchymal stem cells (MSC) markedly attenuates the severity of endotoxin-induced ALI. This effect is likely mediated by paracrine/endocrine repair mechanism of MSC, and not rather than cellular engraftment mechanisms (43). Recently, in addition to its direct antimicrobial effect, tylvalosin was reported to exhibit anti-inflammatory property and attenuates ALI through suppression of NF-$\kappa$B activation (44).

### Pulmonary fibrosis

Utilizing alveoli epithelia-specific Shp2-knockout mice, Yuehai Ke (Zhejiang University)’s group identified a novel role of Src homology phosphotyrosyl phosphatase 2 (Shp2) in surfactant homeostasis, which demonstrated Shp2 deregulation induces spontaneous pulmonary fibrosis with minimal inflammation (45). They further exhibited that disruption of Shp2 promoted the association of JAK1 with interleukin 4 (IL-4Ra), resulting in M2 skewing through enhancing IL-4-mediated JAK1/STAT6 activation (46). Statin use is associated with interstitial lung abnormalities among smokers with COPD. Gene studies suggest statins may influence the susceptibility to pulmonary fibrosis. Jinfu...
Xu (Tongji University) revealed bleomycin-induced lung inflammation and fibrosis in mice via enhanced the NOD-like receptor family, pyrin domain containing 3 (NLRP3)-inflammasome activation (47). Lingsong Li (CAS) and coworkers found that bone marrow derived-MSCs (BMSCs) maybe involved in lung fibrosis. They demonstrated the underlying mechanism to be lysophosphatidic acid (LPA)-induced BMSC differentiation into myofibroblast and ECM secretion via LPA1 (lysophosphatidic acid type-1 receptor) (48). Qinhua Liu (Shandong University) demonstrated early endostatin administration alleviated fibrotic changes in bleomycin-induced pulmonary fibrosis by decreasing microvascular density, infiltrating inflammatory cells, and increasing alveolar type II cell apoptosis. The levels of TNF-α and TGF-β1 were decreased after endostatin treatment (49). Dexiang Xu (Anhui Medical University) delineated the protective mechanisms of melatonin in bleomycin-induced pulmonary fibrosis include inhibition of GRP78 up-regulation, elevation of the cleaved activating transcription factor-6 (ATF6) and activation of pulmonary eIF2α. Melatonin also repressed pulmonary inositol requiring ER-to-nucleus signal kinase-1α (IRE1α) phosphorylation, consequently inhibiting activation of x-box binding protein-1(XBP-1) and JNK (50). Baofeng Yang (Harbin Medical University) identified the involvement of miR-26a in epithelial-mesenchymal transition (EMT) during idiopathic pulmonary fibrosis. Inhibition of miR-26a resulted in transformation of lung epithelial cells into myofibroblasts whereas forced expression of miR-26a alleviated transforming growth factors-β (TGF-β1) and bleomycin-induced EMT (51).

**COPD**

Nanshan Zhong organized a large-population, spirometry-based, cross-sectional survey of COPD, and reported the overall prevalence of COPD in China to be 8.2% (men, 12.4%; women, 5.1%). The prevalence of COPD was significantly higher in rural residents, elderly patients, smokers, and in those with lower body mass index, less education, poor kitchen ventilation, occupational exposure to dust or biomass fuels, childhood pulmonary problems or family history of pulmonary diseases (52). Further studies demonstrated indoor pollutants from biomass fuels and Chinese water-pipe smoking are important risk factors for non-smoking women with COPD (53, 54). ChemR23 and tissue inhibitor of metalloproteinase-1 were identified as potential protein biomarkers of COPD (54). Zhong’s team also revealed that carbocisteine, a muco-lytic agent, reduced the yearly COPD exacerbation (55). Cigarette smoke (CS) is a major risk factor for COPD development. Huahao Shen (Zhejiang University) demonstrated Tc17 cells, as an important source of IL-17A, were associated with CS-induced emphysema and deoxyribonucleic acid damage (56). Fugiang Wen (Sichuan University) demonstrated astragaloside attenuated CS-induced airway inflammation via its anti-inflammatory and antioxidant properties, and sildenafil inhibited airway inflammation and mucus production via nitric oxide/cyclic guanosine 3',5'-monophosphate pathway (57, 58). MSCs were reported to relieve airway inflammation and emphysema in CS-exposed rat models, through the inhibition of cyclooxygenase-2(COX-2)/prostaglandin E2 (PGE2) in alveolar macrophages (59). Ping Chen (Central-South University) demonstrated mitochondrial transcription factor (mtTFA) levels are associated with apoptosis of pulmonary vascular endothelial cells. Aberrant mtTFA methylation may play an important role in COPD pathogenesis (60). Jiajun Xie (Huzhong University of Science and Technology) found IL-33 expression levels are increased in COPD patients and related to airway and systemic inflammation (61). Recently, Jiajun Xie (Guangzhou Medical University) demonstrated that functional germline variant c.353T>C (p.Val118Ala) of Snai1 confers consistently decreased risks of lung cancer and COPD (62).

**Asthma**

Asthma is characterized by airway inflammation, tissue injury/remodeling, bronchoconstriction and mucus hypersecretion. Nanshan Zhong and coworkers, in a cross-sectional national survey of 6304 patients, demonstrated house dust mites were the most prevalent allergens in patients with asthma and/or rhinitis in China. There were significant differences in sensitization pattern in patients from different geographical areas and age groups (63). Zhong et al. also demonstrated that the combination of cumulative dose for Leukotriene D(4) and potency ratio might be useful in identifying leukotriene-responsive asthmatic patients. Leukotriene D(4) and methacholine bronchial provocation tests are measurements of airway responsiveness (64). One year treatment with Alutard SQ house dust mite immunotherapy significantly reduced symptoms and medication use in patients with mild to moderate allergic asthma (65). Recently, Jia Yin (Peking Union Medical College) reported 12 months of daily treatment with sublingual mite allergen (mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts) was well tolerated and effectively controlled disease in patients with moderate (but not
mild) persistent asthma (66). Huanzhong Shi (Capital Medical University) provided direct evidence that IL-4 and IL-5 increase airway responsiveness and airway infiltration of activated eosinophils in patients with allergic bronchial asthma (67, 68). Serum concentrations of both sCD86 and sCTLA-4 increased after allergen inhalation in sensitized asthmatic subjects, with levels correlating to asthma severity (69–72). Eosinophils not only act as terminal effector cells, but also actively modulate immune responses by promoting expansion of Th2 cells (73). Huahao Shen's team reported treatment with anti-CCR3 or dexamethasone can inhibit migration and differentiation of CD34+ progenitor cells by regulating the eotaxin/CCR3 axis in asthmatic mice, demonstrating a novel molecular mechanism for the migration and in situ differentiation of CD34+ progenitors (74). Exogenous IL-17 was shown to protect against allergic asthma, likely through inhibition of eosinophil differentiation in bone marrow (75). Their following work demonstrated airway epithelial protein tyrosine phosphatase SHP2 modulated TGF-β1 activities, leading to airway remodeling and lung dysfunction (76). Changchong Li (Wenzhou Medical College) demonstrated PI3K and Notch signal pathways coordinately regulate activation and proliferation of T lymphocytes in asthma by up-regulating cyclinD1 and down-regulating p27kip1 of CD4 T lymphocytes (77). Guanghong Tan (Hainan Medical College) verified Ag43/Fcε3, as a protein vaccine, produced neutralizing auto-antibodies to IgE, induced significant anti-asthma effects, and regulated IgE and Th cytokines in a murine asthma model (78). Rui He (Fudan University) showed chimerin attenuated allergic airway inflammation and hyperreactivity by suppressing airway recruitment of CD11c+ CD11b− DCs via inhibition of CCL2 secretion by active lung epithelial cells (79). Guohua Zhen (Huazhong University of Science and Technology) found asthma patients with high epithelial expression of IL-25 had greater airway hyperresponsiveness, more airway and blood eosinophils, higher serum IgE, more subepithelial thickening and higher expression of Th2 signature genes. These patients responded well to inhaled corticosteroid treatment compared to IL-25-low patients (80).

**Pulmonary hypertension**

Zhicheng Jing (Tongji University) and coworkers reported the baseline characteristics and survival rates of Chinese patients with idiopathic and familial PH. After mean follow up of 40.1 months, the survival rates at 1, 2, 3 and 5 years were 68.0%, 56.9%, 38.9% and 20.8%, respectively. This study raises international concern about PH-related social burden in developing countries (81, 82). Through two prospective, open-label, multicenter clinical studies, ZhiCheng Jing reported the safety and efficacy oral sildenafil in Chinese patients with PH and Eisenmenger syndrome (83). He also participated in the registry study about the clinical features and prognosis of pediatric pulmonary hypertension, a part of the Pediatric Pulmonary Hypertension registry (84), and proposed the QRS duration and serum high-density lipoprotein levels might serve as an indicator of disease severity and prognosis in idiopathic PH patients (85, 86). Jian Wang (Guangzhou Medical College) and coworkers demonstrated sildenafil inhibits PH by reducing canonical transient receptor potential (TRPC) protein expression and intracellular calcium concentration. Sildenafil inhibits hypoxia-induced TRPC expression in pulmonary arterial smooth muscle via the cGMP-PKG-PPARγ axis (87, 88). Wang first demonstrated that there are expressions of TRPC, transient receptor potential vanilloid (TRPV) and store-operated calcium entry in pulmonary venous smooth muscle, providing new insight into the pathogenesis of PH (89). Furthermore, he demonstrated the role of HIF-1-BMP2/4-TRPC pathway in hypoxic PH, which held great implications for future research (90, 91). Qinghua Hu (Huazhong University of Science and Technology) and coworkers have focused on the molecular mechanisms and pathophysiological significance of calcium signal kinetics-regulated downstream cellular events in PH. His work demonstrated calcium oscillation frequency cooperates with reactive oxygen species to efficiently regulate agonist-stimulated gene expression (92) and established that calcium oscillation frequency regulates transcription and gene expression through cumulated spike duration (93). He also revealed a novel mechanism underlying hypoxic pulmonary vasoconstriction as the critical role of calcium-sensing receptor in orchestrating reactive oxygen species and Ca2+ signaling (94) and suggested glyceraldehydes-3-phosphate dehydrogenase plays a critical role in determining the superior functions of female BM-MSC in cell therapy against PH by regulating Ca2+ signal-associated cellular behaviours (95). Chen Wang and coworkers first demonstrated that the changes in membrane translocation and protein expression of cPKCa, βI, βII and nPKCδ are involved in the development of hypoxia-induced rat PH (96). He also confirmed that the septal angle is a useful tool for estimating pulmonary vascular resistance in patients with chronic thromboembolic PH (97). Notch signaling has been implicated in the development of PH, and soluble Jagged1 (sJag1) inhibits this signaling pathway. Yongguang Xiao (Wuhan
University) and coworkers demonstrated that the potential therapeutic use of the sJag1 may inhibit the proliferation of pulmonary arterial smooth muscle cells (PASMCs) and restore the differentiated PH-PASMCs phenotype by interference with Notch–Herp2 signaling (98). Jinchuan Yan (Jiangsu University) and coworkers provided evidence that docosahexaenoic acid effectively suppressed hypoxia-induced PASMCs proliferation, migration, phenotype modulation and ERK1/2 activation in vitro (99). Bo Zhang (Fourth Military Medical University) and coworkers demonstrated oxymatrine treatment attenuated right-ventricular systolic pressure and pulmonary arterial remodeling by suppressing expression of inflammatory cytokines and accumulation of leukocytes and T cells. Under hypoxic conditions, oxymatrine significantly upregulated expression of Nrf2 and antioxidant protein superoxide dismutase-1 (SOD1) and HO-1, but downregulated hydroperoxide levels in PASMCs (100).

Hypoxic-inducible p27 in pulmonary artery SMCs inhibited the hypoxia-induced proliferation of pulmonary artery SMCs and arrested more cells at G0/G1 phase, and ultimately prevented hypoxic PH development (101). Liangxing Wang (Wenzhou Medical University) and coworkers reported recently salidroside, an active ingredient isolated from Rhodiola rosea, can attenuate chronic hypoxia-induced PH by promoting PASMCs apoptosis via an A2aR related mitochondria dependent pathway (102).

**Pleural diseases**

Huanzhong Shi and his coworkers have extensively explored the roles of CD4$^{+}$CD25$^{+}$ T cells, Th17 cells, Th22 cells and Th 9 cells in the pathogenesis of malignant pleural effusion (MPE) and tuberculosis pleural effusion (TPE). Upreregulated CD4$^{+}$CD25$^{+}$ T cells express high levels of Foxp3 transcription factor, potently suppressing the proliferation of CD4$^{+}$CD25$^{+}$ T cells in MPE, and cytotoxic lymphocyte-associated antigen-4 is involved with the suppressive activity of pleural CD4$^{+}$CD25$^{+}$ T cells (103). CCL2 may be responsible for the infiltration of CD4$^{+}$CD25(high) T cells into the pleural space (104). The accumulation of Th17 cells in MPE predicted improved patient survival whereas increased Th22 cell numbers in MPE promoted the proliferation and migratory activity of cancer cells (105, 106). Th9 cells in both MPE and blood expressed increased CCR6 upon their surface. Furthermore, anti-CCL20 mAb significantly inhibited the ability of MPE or supernatants to stimulate Th9 cell chemotaxis. The majority of Th9 cells in MPE exhibited effector memory cell phenotype (107). Another study performed also by Shi et al. showed Th17/Treg imbalance exists in MPE and pleural CD39$^{+}$ Tregs inhibit generation and differentiation of Th17 cells via a LAP-dependent mechanism (108). These data provide the basis for developing immune-boosting treatment strategies for MPE.

In TPE, the increased pleural CD4$^{+}$CD25$^{+}$ T cells express increased Foxp3 transcription factor (109). Pleural mesothelial cells (PMCs) were able to function as antigen-presenting cells to stimulate CD4$^{+}$ T-cell proliferation and Th22-cell differentiation. The overrepresentation of Th22 cells in TPE may be due to pleural cytokines and PMC-produced chemokines. These data suggest a collaborative interplay between PMCs and Th22 cells in TPE (110). Shi’s study also suggested IL-27 in pleural fluid is a sensitive and specific biomarker for diagnosing TPE (111). Changyou Wu (Sun Yat-sen University) and coworkers demonstrated natural killer (NK) cells from TB pleural fluid cells (PFCs) expressed significantly higher levels of chemokine receptor type-3 (CXCR3) and CXCR4 than NK cells from peripheral blood mononuclear cells (PBMCs). IP-10 and SDF-1 induced more NK cell migration from PFCs than PBMCs. CD45RO$^{-}$NK cells produced significantly greater levels of IFN-γ, in IL-12-dependent fashion (112).

**Sleep disordered breathing**

Fang Han (Beijing University) and coworkers have studied narcolepsy in China. His initial retrospective study analyzed narcolepsy onset in 629 subjects diagnosed in Beijing (1998–2010), and reported the occurrence of narcolepsy onset was seasonal, peaking in April, and researching nadir in November, with a 6.7-fold increase from trough to peak. Studying year-to-year variation, he revealed a threefold increase in narcolepsy onset following the 2009 H1N1 winter influenza pandemic (113). He organized a study on gene polymorphisms in Chinese patients with narcolepsy. While there is a strong multiethnic association of polymorphisms in the TCRA and P2RY11 with narcolepsy, but his study does not confirm the association of CPT1B/CHKB in the Chinese population (114). The decreased hypoxic responsiveness in the narcolepsy-cataplexy group is a result of DQB1*0602 status rather than the clinical features of disease (115). Yuanmin Luo (Guangzhou Medical College) and coworkers reported diaphragm electromyography (EMGdi) may be a useful adjunct in measuring esophageal pressure (Pes) for the assessment of neural drive in patients with obstructive sleep apnoea (OSA). Both Pes and EMGdi measurements are useful in accurately
differentiating central from obstructive respiratory events (116). Luo et al. also demonstrated the dead space loading (DSL) was associated with an earlier onset of intolerable dyspnea. During exercise in the presence of an increased external dead space, DSL-induced increases in exertional dyspnea intensity ratings reflected, at least partly, awareness of increased neural respiratory drive, contractile respiratory muscle effort and ventilatory output (117). Chunshui Yu (Tianjin Medical University) and coworkers showed OSA specifically affected the cognitive and sensorimotor-related brain networks but not the visual and auditory networks. This may be a possible explanation for the impaired cognitive and motor functions in OSA (118). Using a canine model, Yue Li (Harbin Medical University) found chronic OSA could shorten atrial effective refractory period, induce altered expression of important channel proteins, and finally lead to atrial structure remodeling (119).

**Lung transplantation**

Since 2002, more than 200 cases of lung transplantation (LT) have been performed in the mainland of China. Jinyu Chen (Wuxi People’s Hospital) and Genin Jiang (Tongji University) have done most LT cases. Chen did 100 cases, including 72 single LT and 28 bilateral LT cases. The mean survival time of these cases was 3.4 years. Jiang has performed over 60 cases of lung transplantation. The cumulative survival rate of his centre was 78%, 70%, 70% and 42% at 1, 3, 5 and 6 years, respectively, (120, 121). Lung ischemia/reperfusion injury remains a significant problem after LT. Using a rat model of LT, Chunxue Bai and coworkers determined curcumin is an alternative therapy for protecting against LT-associated injury by suppressing nuclear factor κB-mediated expression of inflammatory genes (122). Intratracheal administration of p38α shRNA plasmids provided similar therapeutic effects (123). Jingxiang Wu (Shanghai Jiaotong University) and coworkers demonstrated cystathionine-g-lyase protein expression and H₂S generation were dramatically decreased in transplanted rat lungs. NaHS administration significantly improved pulmonary function, decreased lipid peroxidation, lowered myeloperoxidase activity, inhibited IL-1β production and increased IL-10 levels in graft lung tissues. This study suggested H₂S modulation may be a potential therapeutic approach to LT (124).

**Prospect**

With the development of China’s economy in recent years, the NSFC increases the support in the field of respiratory science. Scholarly exchanges and collaborations from China’s premiere experts with international peers continue to grow. Currently, increasing numbers of Chinese scientists in the United States and Europe have relocated to China, become leaders in the respiratory field, and devote their abilities and expertise to the advancement of respiratory medicine.

Within the next 5–10 years, the NSFC will continue to stimulate the basic research of diverse respiratory diseases, including chronic airway diseases, ALI, lung infection, pulmonary hypertension, IPF and sleep disorder. With fast economic development and environment deterioration, the NSFC particularly prompts active research work on environmental factors-related respiratory diseases. In recent years, NSFC has been encouraging the translation of basic discoveries into clinical practice, and also the communication of research advances to the public.

The NSFC processes the applications it receives by means of robust peer review, the best form of review internationally. Its research-funding mechanisms have proven to be a successful example of reform of China’s traditional science and technology system, thereby improving the entire Chinese research culture (125). We believe that the NSFC will continue to actively support the development and advancement of respiratory medicine in China.

**Acknowledgements**

We thank Prof. Xinliang Ma from Thomas Jefferson University for carefully reading and editing this manuscript.

**References**

1. Annals of public health in China. http://www.moh.gov.cn/zwgkt/tjnj/list.shtml.
2. Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet. 2003;362: 1353–8.
3. Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, Zhong N. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129: 1441–52.
4. Zhong N, Zeng G. What we have learnt from SARS epidemics in China. BMJ. 2006;333: 389–91.
5. Mo H, Zeng G, Ren X, et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. Respirology. 2006;11: 49–53.
6. Li BJ, Tang Q, Cheng D, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med. 2005;11: 944–51.
7. Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, Jiang C. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 2008;18: 290–301.
8. Lang J, Yang N, Deng J, Liu K, Yang P, Zhang G, Jiang C. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS One. 2011; 6(8): e23710.
9. Ge XY, Li JL, Yang XL, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503: 535–8.
10. Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;503: 227–31.
11. Yao Y, Bao L, Deng W, et al. An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J Infect Dis. 2014;209: 236–42.
12. Du X, Dong L, Lan Y, et al. Mapping of H3N2 influenza antigenic evolution in China reveals a strategy for vaccine strain recommendation. Nat Commun. 2012;3: 709.
13. Sun Y, Li C, Shu Y, et al. Inhibition of autophagy ameliorates acute lung injury caused by avian influenza A H5N1 infection. Sci Signal. 2012;5: ra16.
14. Li C, Yang P, Sun Y, et al. IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza A (H1N1) virus. Cell Res. 2012;22: 528–38.
15. Li C, Jiao S, Wang G, et al. The immune adaptor ADAP regulates reciprocal TGF-beta1-integrin crosstalk to protect from influenza virus infection. PLoS Pathog. 2015;11: e1004824.
16. Wang C, Cao B, Liu QQ, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med. 2011;155: 217–25.
17. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;368: 1888–97.
18. Chen Y, Liang W, Yang S, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet. 2013;381: 1916–25.
19. Zhang Q, Shi J, Deng G, et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science. 2013;341: 410–4.
20. Xu L, Bao L, Deng W, et al. Novel avian-origin human influenza A(H7N9) can be transmitted between ferrets via respiratory droplets. J Infect Dis. 2014;209: 551–6.
21. Shi Y, Zhang W, Wang F, et al. Structures and receptor binding of hemagglutinins from human-infecting H7N9 influenza viruses. Science 2013;342: 243–7.
22. Wang C, Yu H, Horby PW, et al. Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clin Infect Dis. 2014;58: 1095–103.
23. Huang F, Guo J, Zou Z, et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Commun. 2014; 5: 3595.
24. Xu F, Kang Y, Zhang H, Piao Z, Yin H, Diao R, Xia J, Shi L. Akt1-mediated regulation of macrophage polarization in a murine model of Staphylococcus aureus pulmonary infection. J Infect Dis. 2013;208: 528–38.
25. Liu G, Bi Y, Wang R, Shen B, Zhang Y, Yang H, Wang X, Liu H, Lu Y, Han F. Kinase AKT1 negatively controls neutrophil recruitment and function in mice. J Immunol. 2013;191: 2680–90.
26. Song Z, Zhang J, Zhang X, Li D, Wang H, Xu X, Xu W, Yin Y, Cao J. Interleukin 4 deficiency reverses development of secondary Pseudomonas aeruginosa pneumonia during sepsis-associated immunosuppression. J Infect Dis. 2015; 211: 1616–27.
27. Cao J, Xu F, Lin S, et al. IL-27 controls sepsis-induced impairment of lung antibacterial host defence. Thorax. 2014:69; 926–37.
28. Mao YX, Xu JF, Seeley EJ, Tang XD, Xu LL, Zhu YG, Song YL, Qu JM. Adipose tissue-derived mesenchymal stem cells attenuate pulmonary infection caused by Pseudomonas aeruginosa via inhibiting overproduction of prostaglandin E2. Stem cells. 2015;33: 2331–42.
29. Deng Z, Ma S, Zhou H, et al. Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responses. Nat Immunol. 2013;16: 642–52.
30. Li P, Xu X, Cao E, et al. Vitamin D deficiency causes defective resistance to Aspergillus fumigatus in mice via aggravated and sustained inflammation. PLoS One. 2014:9; e99805.
31. Shao C, Qu J, He L, Zhang Y, Wang J, Yang T, Zhou H, Liu X. Transient overexpression of gamma interferon promotes Aspergillus clearance in invasive pulmonary aspergillosis. Clin Exp Immunol. 2005;142: 233–41.
32. Hu S, Zhang Y, Yu Y, et al. Growth factor receptor bound protein 2-associated binder 2, a scaffolding adaptor protein, negatively regulates host immunity against tuberculosis. Am J Respir Cell Mol Biol. 2014;51: 575–85.
33. Wang J, Li BX, Ge PP, Li J, Wang Q, Gao GF, Qiu XB, Liu CH. Mycobacterium tuberculosis suppresses innate immunity by coopting the host ubiquitin system. Nat Immunol. 2015;16: 237–45.
34. Zheng R, Liu H, Song P, et al. Epstein-Barr virus-induced gene 3 (EBI3) polymorphisms and expression are associated with susceptibility to pulmonary tuberculosis. Tuberculosis (Edinb). 2015;95: 497–504.
35. Jiang J, Wang X, An H, et al. Mucosal-associated invariant T-cell function is modulated by programmed death-1 signaling in patients with active tuberculosis. Am J Respir Crit Care Med. 2014;190: 329–39.
36. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45: 161–70.
37. Song Y, Xu F, Seeley EJ, Ou J, Zhu X, Sun R, Bai C. Acute respiratory distress syndrome: emerging research
in China. Am J Respir Crit Care Med. 2014;190:1090–3.

38. She J, Goolaerts A, Shen J, Bi J, Tong L, Gao L, Song Y, Bai C. KGF-2 targets alveolar epithelia and capillary endothelia to reduce high altitude pulmonary oedema in rats. J Cell Mol Med. 2012;16: 3074–84.

39. Bi J, Tong L, Zhu X, Yang D, Bai C, Song Y, She J. Keratinocyte growth factor-2 intratracheal instillation significantly attenuates ventilator-induced lung injury in rats. J Cell Mol Med. 2014;18: 1226–35.

40. Shyamsunder M, McAuley DF, Ingram RJ, et al. Keratinocyte growth factor promotes epithelial survival and resolution in a human model of lung injury. Am J Respir Crit Care Med. 2014;189: 1520–9.

41. Yang D, Song Y, Wang X, Sun J, Ben Y, An X, Tong L, Bi J, Wang X, Bai C. Deletion of peroxiredoxin 6 potentiates lipopolysaccharide-induced acute lung injury in mice. Crit Care Med. 2011;39: 756–64.

42. Ying H, Kang Y, Zhang H, Zhao D, Xia J, Lu Z, Wang H, Xu F, Shi L. MiR-127 modulates macrophage polarization and promotes lung inflammation and injury by activating the JNK pathway. J Immunol. 2015;194: 1239–51.

43. Qin ZH, Xu JF, Qu JM, Zhang J, Sai Y, Chen CM, Wu L, Yu L. Intrapleural delivery of MSCs attenuates acute lung injury by paracrine/endocrine mechanism. J Cell Mol Med. 2012;16: 2743–53.

44. Zhao Z, Tang X, Zhao X, et al. Tylosalin exhibits anti-inflammatory property and attenuates acute lung injury in different models possibly through suppression of NF-kappaB activation. Biochem Pharmacol. 2014;90: 73–87.

45. Zhang X, Zhang Y, Tao B, et al. Loss of Shp2 in alveoli epithelia induces deregulated surfactant homeostasis, resulting in spontaneous pulmonary fibrosis. FASEB J. 2012;26: 2338–50.

46. Tao B, Jin W, Xu J, Liang Z, Yao J, Zhang Y, Wang K, Cheng H, Zhang X, Ke Y. Myeloid-specific disruption of tyrosine phosphatase Shp2 promotes alternative activation of macrophages and predisposes mice to pulmonary fibrosis. J Immunol. 2014;193: 2801–11.

47. Xu JF, Washko GR, Nakahira K, et al. COPDGene Investigators. Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med. 2012;185: 547–56.

48. Tang N, Zhao Y, Feng R, Liu Y, Wang S, Wei W, Ding Q, An MS, Wen J, Li L. Lysophosphatidic acid accelerates lung fibrosis by inducing differentiation of mesenchymal stem cells into myofibroblasts. J Cell Mol Med. 2014;18: 156–69.

49. Wan YY, Tian GY, Guo HS, Kang YM, Yao ZH, Li XL, Liu QH, Lin DJ. Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats. Respir Res. 2013;14: 56.

50. Zhao H, Wu QQ, Cao LF, Qing HY, Zhang C, Chen YH, Wang H, Liu RR, Xu DX. Melatonin inhibits endoplasmic reticulum stress and epithelial-mesenchymal transition during bleomycin-induced pulmonary fibrosis in mice. PLoS One. 2014;9: e97266.

51. Liang H, Gu Y, Li T, et al. Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during idiopathic pulmonary fibrosis. Cell Death Dis. 2014;5: e1238.

52. Zheng N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176: 753–60.

53. Liu S, Zhou Y, Wang X, Wang D, Lu J, Zheng J, Zhong N, Ran P. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax. 2007;62: 889–97.

54. She J, Yang P, Wang Y, et al. Chinese water-pipe smoking and the risk of COPD. Chest. 2014;146: 924–31.

55. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008;371: 2013–8.

56. Zhou H, Hua W, Jin Y, Zhang C, Che L, Xia L, Zhou J, Chen Z, Li W, Shen H. Tc17 cells are associated with cigarette smoke-induced lung inflammation and emphysema. Respirolgy. 2015;20: 426–33.

57. Chen L, Sun BB, Wang T, et al. Cigarette smoke enhances IL-10 and IL-22 expression in rat airways via nuclear factor-[kappa]B activation. Eur Respir J. 2010;36: 368–45.

58. Wang T, Liu Y, Chen L, et al. Effect of sildenafil on acrolein-induced airway inflammation and mucus production in rats. Eur Respir J. 2009;33: 1122–32.

59. Gu W, Song L, Li XM, Wang D, Guo XJ, Xu WG. Mesenchymal stem cells alleviate airway inflammation and emphysema in COPD through down-regulation of cyclooxygenase-2 via p38 and ERK MAPK pathways. Sci Rep. 2015;5: 8733.

60. Peng H, Yang M, Chen ZY, Chen P, Guan CX, Xiang XD, Cai S, Chen Y, Fang X. Expression and methylation of mitochondrial transcription factor a in chronic obstructive pulmonary disease patients with lung cancer. PLoS One. 2013;8: e82739.

61. Xia J, Zhao J, Shang J, Li M, Zeng Z, Zhao J, Wang J, Xu Y, Xie J. Increased IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2015;308: 619–27.

62. Yang L, Yang X, Ji W, et al. Effects of a functional variant c.353T>C in snail1 on risk of two contextual diseases. Chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med. 2014;189: 139–48.

63. Li J, Sun B, Huang Y, Lin X, Zhao D, Tan G, Wu J, Zhao H, Cao L, Zhong N. China Alliance of Research on Respiratory Allergic Disease. A multicentre study assessing the prevalence of sensitizations in patients with asthma and/or rhinitis in China. Allergy. 2009;64: 1083–92.

64. Guan W, Zheng J, Gao Y, Jiang C, Xie Y, An J, Yu X, Liu W, Zhong N. Leukotriene D4 and methacholine bronchial provocation tests for identifying leukotriene-
responsiveness subtypes. J Allergy Clin Immunol. 2013;131:332–8.
65. Wang H, Lin X, Hao C, Zhang C, Sun B, Zheng J, Chen P, Sheng J, Wu A, Zhong N. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy. 2006;61:191–7.
66. Wang L, Yin J, Fadel R, Montagut A, de Beaumont O, Devillier P. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy. 2014;69:1181–8.
67. Shi HZ, Deng JM, Xu H, Nong ZX, Xiao CQ, Liu ZM, Qin SM, Jiang CX, Liu GN, Chen YQ. Effect of inhaled interleukin-4 on airway hyperreactivity in asthmatics. Am J Respir Crit Care Med. 1998;157: 1818–21.
68. Shi HZ, Xiao CQ, Zhong D, Qin SM, Liu Y, Liang GR, Xu H, Chen YQ, Long XM, Xie ZF. Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics. Am J Respir Crit Care Med. 1998;157: 204–9.
69. Deng JM, Shi HZ, Qin XJ, Xie ZF, Huang CP, Zhong XN. Effects of allergen inhalation and oral glucocorticoid on concentrations of serum-soluble CD86 in allergic asthmatics. Clin Immunol. 2005;11: 178–83.
70. Shi HZ, Xie ZF, Deng JM, Chen YQ, Xiao CQ. Soluble CD86 protein in serum samples of patients with asthma. Thorax. 2004;59: 870–75.
71. Qin XJ, Shi HZ, Qin SM, Kang LF, Huang CP, Zhong XN. Effects of allergen inhalation and oral glucocorticoid on serum soluble CTLA-4 in allergic asthmatics. Allergy. 2005; 60: 774–9.
72. Shi HZ, Mo XY, Zhong XN. Soluble CTLA-4 in sera of patients with bronchial asthma. J Asthma. 2005;42: 133–9.
73. Shi HZ, Xiao CQ, Li CQ, Mo XY, Yang QL, Leng J, Chen YQ. Endobronchial eosinophils preferentially stimulate T helper cell type 2 responses. Allergy. 2004;59: 428–35.
74. Ben S, Li X, Xu F, Xu W, Li W, Wu Z, Huang H, Shi H, Shen H. Treatment with anti-CC chemokine receptor 3 monoclonal antibody or dexamethasone inhibits the activation and proliferation of T lymphocytes in an allergic mouse model. Allergy. 2008;63: 1164–76.
75. Tian BP, Hua W, Xia LX, et al. Exogenous interleukin-17A inhibits eosinophil differentiation and alleviates allergic airway inflammation. Am J Respir Cell Mol Biol. 2015;52: 459–70.
76. Qin XJ, Zhang GS, Zhang X, et al. Protein tyrosine phosphatase SHP2 regulates TGF-beta1 production in airway epithelia and asthmatic airway remodeling in mice. Allergy. 2012;67: 1547–56.
77. Zhang W, Nie Y, Chong L, Cai X, Zhang H, Lin B, Liang Y, Li C. PI3K and Notch signal pathways coordinately regulate the activation and proliferation of T lymphocytes in asthma. Life Sci. 2013;92: 890–5.
78. Huang FY, Wang CC, Huang YH, Zhao HG, Guo JJ, Zhou SL, Wang H, Lin YY, Tan GH. Antigen 43/Feepsilon3 chimeric protein expressed by a novel bacterial surface expression system as an effective asthma vaccine. Immunology. 2014;143: 230–40.
79. Zhao L, Yang W, Yang X, et al. Chemerin suppresses murine allergic asthma by inhibiting CCL2 production and subsequent airway recruitment of inflammatory dendritic cells. Allergy. 2014;69: 763–74.
80. Cheng D, Xue Z, Yi L, et al. Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma. Am J Respir Crit Care Med. 2014;190: 639–48.
81. Liu D, Liu QQ, Eyries M, Wu WH, Yuan P, Zhang R, Soubrier F, Jing ZC. Molecular genetics and clinical features of Chinese idiopathic and heritable pulmonary arterial hypertension patients. Eur Respir J. 2012;39: 597–603.
82. Zhang ZN, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart. 2011;97: 1876–81.
83. Berger RM, Beghetti M, Humphl T, Raskob GE, Ivy DD, Jing ZC, Bonnet D, Schulze-Neick I, Barst RJ. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012;379: 537–46.
84. Sun PY, Jiang X, Gomber-Maitland M, Zhao QH, He J, Yuan P, Zhang R, Jing ZC. Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pulmonary arterial hypertension. Chest. 2012;141: 374–80.
85. Zhao QH, Peng FH, Wei H, et al. Serum high-density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol. 2012;110: 433–9.
86. Lu W, Ran P, Zhang D, Peng G, Li B, Zhong N, Wang J. Sildenafil inhibits chronically hypoxic upregulation of canonical transient receptor potential expression in rat pulmonary arterial smooth muscle. Am J Physiol Cell Physiol. 2010;298: C114–23.
87. Wang J, Yang K, Xu L, Zhang Y, Lai N, Jiang H, Zhang Y, Zhong N, Ran P, Lu W. Sildenafil inhibits hypoxia-induced transient receptor potential canonical proteins expression in pulmonary arterial smooth muscle via cGMP-PKG-PPARgamma axis. Am J Respir Cell Mol Biol. 2013;49: 231–40.
88. Peng G, Lu W, Li X, Chen Y, Zhong N, Ran P, Wang J. Expression of store-operated Ca2+ entry and transient receptor potential canonical and vanilloid-related proteins in rat distal pulmonary venous smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2010;299: L621–30.
89. Lu W, Ran P, Zhang D, Lai N, Zhong N, Wang J. Bone morphogenetic protein 4 enhances canonical transient receptor potential expression, store-operated Ca2+ entry, and basal [Ca(2+)]i in rat distal pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol. 2010;299: C1370–8.
90. Zhang Y, Lu W, Yang K, Xu L, Lai N, Tian L, Jiang Q, Duan X, Chen M, Wang J. Bone morphogenetic protein 2 decreases TRPC expression, store-operated Ca(2+) entry, and basal [Ca(2+)]i in rat distal pulmonary arterial
smooth muscle cells. Am J Physiol Cell Physiol. 2013;304: C833–43.

92. Zhu L, Luo Y, Chen T, Chen F, Wang T, Hu Q. Ca2+ oscillation frequency regulates agonist-stimulated gene expression in vascular endothelial cells. J Cell Sci. 2008;121: 2511–8.

93. Zhu L, Song S, Pi Y, Yu Y, She W, Ye H, Su Y, Hu Q. Cumulated Ca2+(+) spike duration underlies Ca2+(+) oscillation frequency-regulated NF-kappaB transcriptional activity. J Cell Sci. 2011;124: 2591–601.

94. Zhang J, Zhou J, Cai L, Lu Y, Wang T, Zhu L, Hu Q. Extracellular calcium-sensing receptor is critical in hypoxic pulmonary vasconstriction. Antioxid Redox Signal. 2012; 17: 471–84.

95. Tan R, Li J, Peng X, Zhu L, Cai L, Wang T, Su Y, Irani K, Hu Q. GAPDH is critical for superior efficacy of female bone marrow-derived mesenchymal stem cells on pulmonary hypertension. Cardiovasc Res. 2013;100: 19–27.

96. Shi Y, Wang C, Han S, Pang B, Zhang N, Wang J, Li J. Determination of PKC isoform-specific protein expression in pulmonary arteries of rats with chronic hypoxia-induced pulmonary hypertension. Med Sci Monit. 2012; 18: BR69–75.

97. Liu M, Ma ZH, Guo XJ, Wang SK, Chen XY, Yang YH, Wang C. A septal angle measured on computed tomographic pulmonary angiography can noninvasively estimate pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension. J Thorac Imaging. 2012;27: 325–30.

98. Xiao Y, Gong D, Wang W. Soluble JAGGED1 inhibits pulmonary hypertension by attenuating notch signaling. Arterioscler Thromb Vasc Biol. 2013;33: 2733–9.

99. Yan J, Chen R, Liu P, Gu Y. Docosahexaenoic acid inhibits development of hypoxic pulmonary hypertension: in vitro and in vivo studies. Int J Cardiol. 2013; 168: 4111–6.

100. Zhang B, Niu W, Xu D, et al. Oxymatrine prevents hypoxia- and monocrotaline-induced pulmonary hypertension in rats. Free Radic Biol Med. 2014;69: 198–207.

101. Luo Y, Zhang B, Dong HY, Liu Y, Li ZC, Dong MQ, Gao YQ. Prevention of hypoxic pulmonary hypertension by hypoxia-inducible expression of p27 in pulmonary artery smooth muscle cells. Gene Ther. 2014;21: 751–8.

102. Huang X, Zou L, Yu X, et al. Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent apoptosis pathway. Mol Cell Cardiol. 2015;82: 153–66.

103. Chen YQ, Shi HZ, Qin XJ, Mo WN, Liang XD, Huang ZX, Yang HB, Wu C. CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion. Am J Respir Crit Care Med. 2005;172: 1434–9.

104. Qin XJ, Shi HZ, Deng JM, Liang QL, Jiang J, Ye ZJ. CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res. 2009;15: 2231–7.

105. Ye ZJ, Zhou Q, Gu YY, Qin SM, Ma WL, Xin JB, Tao XN, Shi HZ. Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J Immunol. 2010;185: 6348–54.

106. Ye ZJ, Zhou Q, Yin W, Yuan ML, Yang WB, Xiang F, Zhang JC, Xin JB, Xiong XZ, Shi HZ. Interleukin 22-producing CD4+ T cells in malignant pleural effusion. Cancer Lett. 2012;326: 23–32.

107. Bu XN, Zhou Q, Zhang J, Ye ZJ, Tong ZH, Shi HZ. Recruitment and phenotypic characteristics of interleukin 9-producing CD4+ T cells in malignant pleural effusion. Lung. 2013;191: 385–9.

108. Ye ZJ, Zhou Q, Zhang JC, Li X, Wu C, Qin SM, Xin JB, Shi HZ. CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respir Res. 2011;12: 77.

109. Qin XJ, Shi HZ, Liang QL, Huang LY, Yang HB. CD4+CD25+ regulatory T lymphocytes in tuberculous pleural effusion. Chin Med J (Engl). 2008;121: 581–6.

110. Ye ZJ, Zhou Q, Yuan ML, Du RH, Yang WB, Xiong XZ, Huang B, Shi HZ. Differentiation and recruitment of IL-22-producing helper T cells stimulated by pleural mesothelial cells in tuberculous pleurisy. Am J Respir Crit Care Med. 2012;185: 660–9.

111. Yang WB, Liang QL, Ye ZJ, Niu CM, Ma WL, Xiong XZ, Du RH, Zhou Q, Zhang JC, Shi HZ. Cell origins and diagnostic accuracy of interleukin 27 in pleural effusions. PLoS One. 2012;7: e40450.

112. Fu X, Yang B, Lao S, Fan Y, Wu C. Human memory-like NK cells migrating to tuberculous pleural fluid via IP-10/CXCR3 and SDF-1/CXCR4 axis produce IFN-gamma in response to Bacille Calmette Guerin. Clin Immunol. 2013; 148: 113–23.

113. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol. 2011;70: 410–7.

114. Han F, Lin L, Li J, et al. TCRA, P2RY11, and CPT1B/CHKB associations in Chinese narcolepsy. Sleep Med. 2012;13: 269–72.

115. Han F, Mignot E, Wei YC, et al. Ventilatory chemoresponse sensitivity, narcolepsy-cataplexy and human leukocyte antigen DQB1*0602 status. Eur Respir J. 2010;36: 577–83.

116. Luo YM, Tang J, Jolley C, Steier J, Zheng NS, Moxham J, Polkey MI. Distinguishing obstructive from central sleep apnea events: diaphragm electromyogram and esophageal pressure compared. Chest. 2009;135: 1133–41.

117. Jensen D, O’Donnell DE, Li R, Luo YM. Effects of dead space loading on neuro-muscular and neuro-ventilatory coupling of the respiratory system during exercise in healthy adults: implications for dyspnea and exercise tolerance. Respir Physiol Neurobiol. 2011;179: 219–26.

118. Zhang Q, Wang D, Qin W, Li Q, Chen B, Zhang Y, Yu C. Altered resting-state brain activity in obstructive sleep apnea. Sleep. 2013;36: 651–59.
119. Zhao J, Xu W, Yun F, et al. Chronic obstructive sleep apnea causes atrial remodeling in canines: mechanisms and implications. Basic Res Cardiol. 2014;109: 427.
120. Mao W, Chen J, Zheng M, Wu B, Zhu Y. Initial experience of lung transplantation at a single center in China. Transplant Proc. 2013;45: 349–55.
121. He WX, Jiang GN, Ding JA, et al. Lung transplantation in a Chinese single center: 7 years of experience. Chin Med J (Engl). 2011;124: 978–82.
122. Sun J, Guo W, Ben Y, Jiang J, Tan C, Xu Z, Wang X, Bai C. Preventive effects of curcumin and dexamethasone on lung transplantation-associated lung injury in rats. Crit Care Med. 2008;36: 1205–13.
123. Lv X, Tan J, Liu D, Wu R, Cui X. Intratracheal administration of p38alpha short-hairpin RNA plasmid ameliorates lung ischemia-reperfusion injury in rats. J Heart Lung Transplant. 2012;31: 655–62.
124. Wu J, Wei J, You X, Chen X, Zhu H, Zhu X, Liu Y, Xu M. Inhibition of hydrogen sulfide generation contributes to lung injury after experimental orthotopic lung transplantation. J Surg Res. 2013;182: e25–33.
125. Zare RN, Winnacker EL. China’s science funding. Science. 2011;334: 433.